✦ LIBER ✦

O-195 Activating mutations (muts) in the tyrosine kinase (TK)domain of the epidermal growth factor receptor (EGFR) and of the platelet-derived growth factor receptor α (PDGFRA) in gefitinib-treated non-small-cell lung cancer (NSCLC) patients

✍ Scribed by Taron, M.; Santarpia, C.; Ichinose, Y.; Mok, T.; Massuti, B.; Queralt, C.; Sanchez, J.; Jahan, T.; Jablons, D.; Rosell, R.

Book ID: 118572744
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 156 KB
Volume: 49
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(05)80330-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mutations in the Tyrosine Kinase Domain

Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer

✍ Yang, S. H. 📂 Article 📅 2005 🏛 American Association for Cancer Research 🌐 English ⚖ 134 KB

Activating Mutations in the Epidermal Gr

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

✍ Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; 📂 Article 📅 2004 🏛 Massachusetts Medical Society 🌐 English ⚖ 442 KB

PD-151 Mutations in the epidermal growth

PD-151 Mutations in the epidermal growth factor receptor (EGFR): Retro-and prospective observations in non-small cell lung cancer (NSCLC) patients (pts) treated with gefitinib

✍ Nederlof, P.; Boerrigter, L.; van 't Veer, L.; Baas, P.; van Zandwijk, N. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 261 KB

Mutations of the epidermal growth factor

Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients

✍ Murray, S.; Timotheadou, E.; Linardou, H.; Vrettou, A.V.; Kostopoulos, I.; Skric 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 413 KB

Epidermal growth factor receptor (EGFR)

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)

✍ Elena María Martínez-Navarro; Joseba Rebollo; Ramón González-Manzano; Manuel Sur 📂 Article 📅 2011 🏛 Springer Milan 🌐 Spanish ⚖ 230 KB

PD-159 Mutation in the tyrosine kinase d

PD-159 Mutation in the tyrosine kinase domain of epidermal growthfactor receptor (EGFR) is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer (NSCLC)

✍ Tsai, C.; Chiu, C.; Chou, T.; Li, L.; Chang, K.; Chen, Y.; Tsai, S.; Perng, R. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 139 KB